Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Reven

Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Reven

Supernus and Indivior merge as equals to form $2.2B CNS pharma leader with $125M annual cost synergies. Leverage <1x enables strategic M&A pursuit in psychiatry/neurology/addiction markets where AI diagnosis trends are reshaping treatment.